The sequencing sector is changing fast, but Pacbio believes its technology can hold out against its rivals.
Stock leaps in early trade, but to justify its huge valuation the technology might have to improve.
The sequencing group’s $8bn deal to recapture Grail leaves shareholders unimpressed.
Despite insisting last year that it was no longer for sale, Qiagen falls to Thermo Fisher for $10bn.
Even if the sequencing giant doesn't suffer in the short term from the death of its bid for Pacbio, long-read tech is nipping at its heels.
Illumina’s $1.2bn buy of Pacific Biosciences raises questions about why it shunned another long-read sequencing player, Oxford Nanopore Technologies.